Peptides of human Papilloma virus for use in human T cell...

Details Peptides of human Papilloma virus for use in human T cell... Peptides of human Papilloma virus for use in human T cell...

2008-04-29

2008-04-29

Minnifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S185100, C424S204100, C424S277100, C530S300000, C530S327000, C530S328000, C514S002600

Reexamination Certificate

active

07364741

ABSTRACT:
A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.

REFERENCES:
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5415995 (1995-05-01), Schoolnik et al.
patent: 5550214 (1996-08-01), Eberlein et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5679509 (1997-10-01), Wheeler et al.
patent: 5686068 (1997-11-01), Melief et al.
patent: 5932412 (1999-08-01), Dillner et al.
patent: 6013258 (2000-01-01), Urban et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6147187 (2000-11-01), Melief et al.
patent: 6183745 (2001-02-01), Tindle et al.
patent: 6183746 (2001-02-01), Urban et al.
patent: 6218363 (2001-04-01), Baserga et al.
patent: 6242176 (2001-06-01), Kast et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: 6548299 (2003-04-01), Pykett et al.
patent: 6582704 (2003-06-01), Urban et al.
patent: 6620510 (2003-09-01), Taguchi et al.
patent: 6783763 (2004-08-01), Choppin et al.
patent: 6797491 (2004-09-01), Neefe et al.
patent: 6838084 (2005-01-01), Jochmus et al.
patent: 6861234 (2005-03-01), Simard et al.
patent: 7026443 (2006-04-01), Sette et al.
patent: 2002/0110566 (2002-08-01), Neefe et al.
patent: 2003/0099634 (2003-05-01), Vitiello et al.
patent: 2003/0170268 (2003-09-01), Neefe et al.
patent: 2003/0175285 (2003-09-01), Klinguer-Hamour et al.
patent: 2004/0091479 (2004-05-01), Nieland et al.
patent: 2004/0106551 (2004-06-01), Khleif et al.
patent: 2004/0141081 (2004-07-01), Morrison et al.
patent: 2004/0147044 (2004-07-01), Mittelman et al.
patent: 2004/0170644 (2004-09-01), Mailere et al.
patent: 2004/0235741 (2004-11-01), Neefe et al.
patent: 2004/0258708 (2004-12-01), Jochmus et al.
patent: 2005/0033025 (2005-02-01), Choppin et al.
patent: 2005/0048467 (2005-03-01), Sastry et al.
patent: 2005/0100928 (2005-05-01), Hedley et al.
patent: 2005/0130920 (2005-06-01), Simard et al.
patent: 2005/0142541 (2005-06-01), Lu et al.
patent: 2005/0181458 (2005-08-01), Harding et al.
patent: 2006/0079453 (2006-04-01), Sidney et al.
patent: 2006/0094649 (2006-05-01), Keogh et al.
patent: 0257754 (1988-03-01), None
patent: 0375555 (1990-06-01), None
patent: 0456197 (1991-11-01), None
patent: 0593754 (1994-04-01), None
patent: WO 9205248 (1992-04-01), None
patent: WO 93/22338 (1993-11-01), None
Matlashewski et al. 1986. The Expression of Human Papillomavirus type 18 E6 . . . J. Gen Viral 67:1909-16.
Kast et al. 1991. In vivo efficacy of virus-derived peptide . . . Immunol. Letters. 30:229-232.
Kast. et al. 1991. Protection against lethal Sendai virus infection by . . . PNAS. 88:2283-2287.
Bowie et al. 1990. Science 247:1306-1310.
Houghten et al. 1986. Vaccines 86 pp. 21-25.
Kast et al, J. Immunology, 1994, 152:3904-3912.
Burger et al, J. National Cancer Institute, 1996 88/19:1361-1368.
Rudolf et al, Clinical Cancer Research, Mar. 2001, 7:788s-795s.
Feltkamp et al, Eur. J. Immunology, 1993, 23:2242-2249.
Zehbe et al, Cancer Research, 1998, 58:829-833.
Watts et al, Int. J. Cancer, 2002, 97:868-874.
Kennedy et al, J. Virology, Apr. 1991, 65/4:2093-2097.
Tan et al, Cancer Research, 1995, 55:4599-4605.
Dillner, Int. J. Cacner, 1990, 46:703-711.
Seedorf et al, Virology, 1985, 145:181-185.
Selvey et al, J. Virological Methods, 1992, 37:119-127.
Tindle et al, PNAS, USA, 1991, 88/13:5887-5891.
Altmann et al, Eur. J. Cancer, 1992, 28(2/3):326-333.
Comerford et al, J. Virology, Sep. 1991, 65/9:4681-4690.
Gariglio et al, Archives of Medical Research, 1998, 29/4:279-284.
Hoppe-Seyler et al, Molecular Carcinogenesis, 1994, 10:134-141.
Azoury-Ziadeh et al, Viral Immunol., 1999, 12/4:297-312.
Stauss et al, PNAS, USA, 1992, 89/17:7871-7875.
Stanley, Current Opinion in Molecular Therapeutics, 2002, 4/1:15-22.
Welters et al, Cancer Research, 2003, 63:636-641.
de Jong et al, Cancer Research, 2004, 64:5449-5455.
de Jong et al, Cancer Research, 2002, 62:472-479.
Lehtinen et al, Am. J. Obsete. Gynecol., 2003, 188:49-55.
Lowy et al, PNAS, USA, 1994, 91:2436-2440.
Breitburd et al, Seminars in Cancer Biology, 1999, 9:431-445.
Altmann et al “Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7”; European Journal of Cancer, vol. 28, No. 2/3, Feb. 1992, pp. 326-333.
Tindle et al “A ‘public’ T-helper epitope of the E7 transforming protein . . . ” Proc. Natl Acad. Sci. USA. vol. 88, No. 13, Jul. 1991, pp. 5887-5891.
Comerford et al “Identification of T- and B-epitopes of the E-7 protein of human papillomavirus type 16”, Journal of Virology, vol. 65, No. 9, Sep. 1991, pp. 4681-4690.
Stauss et al “Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell . . . ”, Proc. Natl. Acad. Sci. USA, vol. 89, No. 17, Sep. 1, 1992, Washington US pp. 7871-7875.

Affiliated with

Also associated with

Rating

Peptides of human Papilloma virus for use in human T cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides of human Papilloma virus for use in human T cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides of human Papilloma virus for use in human T cell... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2791767